3-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]-7-ethoxy-5,7-dioxoheptanoic acid | 721920-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]-7-ethoxy-5,7-dioxoheptanoic acid
• CAS: 721920-85-0
• 化学式: C₁₈H₁₈ClNO₅S
• 分子量: 395.864
• InChiKey: IAGZPFMKMOFEHM-UHFFFAOYSA-N

物化性质

• 沸点：
  564.0±60.0 °C(Predicted)
• 密度：
  1.347±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]-7-ethoxy-5,7-dioxoheptanoic acid 在 盐酸 、 sodium hydroxide 、 盐酸羟胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 Ethyl 3-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]-4-(3-oxo-1,2-oxazol-5-yl)butanoate
  参考文献：
  名称：

  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

  摘要：

  We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.045
• 作为产物：
  描述：

  4-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]dihydro-2H-pyran-2,6-(3H)-dione 、 乙酸乙酯 在 lithium diisopropyl amide 作用下， 生成 3-[2-(4-chlorophenyl)-1,3-thiazol-5-yl]-7-ethoxy-5,7-dioxoheptanoic acid
  参考文献：
  名称：

  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

  摘要：

  We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.045

文献信息

• [EN] PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE PYRAZOLE EN TANT QU'ANTAGONSITES DES RECEPTEURS DE L'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058761A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the α Vβ5 integrin without significantly inhibiting the α Vβ6 integrin.

  本发明涉及包含式(I)化合物的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• Pyrazole compounds as integrin receptor antagonists derivatives
  申请人：Penning D. Thomas

  公开号：US20050004200A1

  公开（公告）日：2005-01-06

  The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.

  本发明涉及一类由公式I表示的化合物或其药学上可接受的盐，包括由公式I的化合物组成的药物组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素而不显著抑制αVβ6整合素的方法。
• Heteroarylalkanoic acids as integrin receptor antagonists derivatives
  申请人：Boys L. Mark

  公开号：US20050043344A1

  公开（公告）日：2005-02-24

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.

  本发明涉及包含式I的化合物或其药学上可接受的盐的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES
  申请人：Pharmacia Corporation

  公开号：EP1572691A1

  公开（公告）日：2005-09-14
• HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Pharmacia Corporation

  公开号：EP1592421A1

  公开（公告）日：2005-11-09